However, there is strong epidemiological evidence that CB1R inhibition over a long-term timeframe puts people at risk for adverse psychiatric effects and therefore CB1R antagonists need to be devoid of central psychiatric effects in order to be a useful therapeutic strategy in the pathogenesis of toxin-induced liver diseases. Here, CNR1 is linked to liver disorder.